KOC
DNA icon

Koss-Olinger Consulting’s Ginkgo Bioworks DNA Stock Holding History

Koss-Olinger Consulting’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250
Closed -$3K – 278
2024
Q2 		$3K Buy
+250
New +$7.46K ﹤0.01% 267
2024
Q1 		– Sell
-250
Closed -$17K – 112
2023
Q4 		$17K Hold
250
– – ﹤0.01% 312
2023
Q3 		$18K Hold
250
– – ﹤0.01% 274
2023
Q2 		$19K Hold
250
– – ﹤0.01% 279
2023
Q1 		$13K Buy
+250
New +$15.8K ﹤0.01% 261

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Koss-Olinger Consulting's DNA Position: Q3 2024 in Review

Koss-Olinger Consulting sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 250 shares — an estimated $3K sold.

Koss-Olinger Consulting first reported a position in DNA in Q1 2023 and held it in 5 quarters. The position peaked at $19K in Q2 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Koss-Olinger Consulting reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Koss-Olinger Consulting sold 250 Ginkgo Bioworks shares in Q3 2024, an estimated $3K.
  • Koss-Olinger Consulting first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 5 quarters.
  • Koss-Olinger Consulting's Ginkgo Bioworks position peaked at $19K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Koss-Olinger Consulting's 13F filing for Q3 2024, filed 21 Oct 2024.